Botsi has raised $1.5 million in pre-seed funding to expand its AI-powered monetization platform for consumer subscription applications. The financing came from Telegraph Ventures, Plain Sight Capital, Atlanta Tech Angels, VentureSouth and angel investors.
Botsi is developing an alternative to the traditional approach of showing the same subscription paywall or offer to large groups of users.
Instead, its technology selects different subscription offers for individual users in real time, using behavioral information and context to determine which offer is most likely to convert or retain each customer.
The underlying models continue learning as a company’s traffic mix, product and competitive environment change, allowing pricing and offers to adjust over time rather than relying solely on periodic A/B tests.
Since launching in the fourth quarter of 2025, Botsi said customers including Fitness AI, Sleepiest and Reading.com have recorded revenue and lifetime-value increases ranging from 15% to 75%.
The platform operates across consumer subscription applications on both web and mobile and is designed to select offers that increase revenue while reducing customer churn.
Botsi is headquartered in New York and was founded by Jacob Rushfinn, Jason Schubert and William Schubert.
Rushfinn has more than a decade of experience in mobile app growth and monetization, including positions at Automattic and Balance, before advising B2C subscription applications on monetization strategy.
Jason and William Schubert previously founded inBrain.ai, a platform enabling consumer apps to monetize users through rewarded experiences.
KEY QUOTES:
“For years, B2C companies have A/B tested offers and shipped the one that works best on average. Who wants to be average? Your users have different needs, and different reasons for paying, and forcing one offer on all of them costs you revenue and customers.”
Jacob Rushfinn, Co-Founder and CEO of Botsi
“Great teams find real problems. Botsi’s founders bring the credibility and expertise to turn subscription pricing from guesswork into science, and that’s why we invested in them.”
Luis Gutierrez Roy, General Partner at Telegraph Ventures
